Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing’s Sarcoma

Donald D. Rao1, Christopher Jay1, Zhaohui Wang1, Xiuquan Luo1, Padmasini Kumar2, Hilary Eysenbach1, Maurizio Ghisoli1,4,5, Neil Senzer2,3, John Nemunaitis1,3,4,5

1 Strike Bio, Carrollton, Texas, USA; 2 Gradalis, Inc., Dallas, Texas, USA; 3 Mary Crowley Cancer Research Centers, Dallas, Texas, USA; 4 Texas Oncology, P.A., Dallas, Texas, USA; 5 Medical City Dallas Hospital, Dallas, Texas, USA

The EWS/FLI1 fusion gene is well characterized as a driver of Ewing’s sarcoma. Bi-shRNA EWS/FLI1 is a functional plasmid DNA construct that transcribes both siRNA and miRNA-like effectors each of which targets the identical type 1 translocation junction region of the EWS/FLI1 transcribed mRNA sequence. Previous preclinical and clinical studies confirm the safety of this RNA interference platform technology and consistently demonstrate designated mRNA and protein target knockdown at greater than 90% efficiency. We initiated development of pbi-shRNA EWS/FLI1 lipoplex (LPX) for the treatment of type 1 Ewing’s sarcoma. Clinical-grade plasmid was manufactured and both sequence and activity verified. Target protein and RNA knockdown of 85–92% was demonstrated in vitro in type 1 human Ewing’s sarcoma tumor cell lines with the optimal bi-shRNA EWS/FLI1 plasmid. This functional plasmid was placed in a clinically tested, liposomal (LP) delivery vehicle followed by in vivo verification of activity. Type 1 Ewing’s sarcoma xenograft modeling confirmed dose related safety and tumor response to pbi-shRNA EWS/FLI1 LPX. Toxicology studies in mini-pigs with doses comparable to the demonstrated in vivo efficacy dose resulted in transient fever, occasional limited hypertension at low- and high-dose assessment and transient liver enzyme elevation at high dose. These results provide the justification to initiate clinical testing.

INTRODUCTION

Ewing’s sarcoma is the second most frequently diagnosed primary malignant bone tumor in children in the United States with an annual incidence of 2.9 cases per million population. Up to 85% of Ewing’s tumors are characterized by the EWS/FLI (11;22) translocation designated as the EWS/FLI1 fusion gene. Types I and II fusions comprise 60 and 25%, respectively, of the documented breakpoint sites. The EWS/FLI1 fusion gene plays a key role in Ewing’s sarcoma pathogenesis and maintenance and is universally designated as the dominant driver gene. Ewing’s sarcoma fusion gene breakpoint sites are optimal targets for sarcoma specific RNA interference (RNAi)-mediated knockdown that has demonstrated preclinical therapeutic efficacy in both in vitro and in vivo testing. In a variety of models, both antisense oligonucleotides and siRNAs have confirmed targeting relevance and have proven safe in conjunction with down regulation of EWS/FLI1 gene expression.

Sixty to eighty percent of Ewing’s sarcoma patients present with primary metastatic disease and will experience relapse or refractory progression. The median time to relapse is 1.3 years and those who relapse have a poor 1-year/5-year survival from time of relapse. Few respond to second-line therapy and fewer achieve a second remission. Consequently, 5-year survival is severely limited particularly so in patients with “high-risk” disease (i.e., those with relapse within 2 years of front line treatment). In one large retrospective analysis of 714 patients from time of first relapse, the 1-year overall survival (OS) was 43%, 5-year OS was 13%, and 10 year OS was 9% Although patients with relapses that occurred within the first 2 years after initial diagnosis, the second OS was 7% and the 5-year event-free survival was 5%. Second-line chemotherapy for relapsed Ewing’s sarcoma has likewise shown limited efficacy with only 9 to 13% of patients achieving a second disease-free remission. There is no standard of care for second-line treatment. Regimens such as topotecan/cyclophosphamide, irinotecan/temozolomide, or docetaxel/gemcitabine have been utilized in second line or later treatment and may prolong life for those who respond.

Unfortunately, for the majority of relapsed patients who do not respond to second-line chemotherapy or who relapse following a second remission, the prognosis is grim with no significant benefit of third-line chemotherapy. In a relatively large retrospective analysis of 195 patients, of the 86% whom did not achieve second remission 97% had died with a median survival of 11.7 months and no patient achieved disease control. Of the 26 patients who achieved a second remission, 12 relapsed and none experienced a third remission (10/12 died and in the first year and 2 were living with uncontrolled disease at 6 and 13 months). Thus, there is desperate need for the development of newer, more effective treatment options in the metastatic, “high risk”, and post-relapse Ewing’s population.

RNAi is a natural cellular regulatory process capable of inhibiting transcriptional, post-transcriptional and translational

Correspondence: John Nemunaitis, Mary Crowley Cancer Research Centers, 12222 Merit Drive, Suite 1500, Dallas, Texas 75251, USA. E-mail: jnemunaitis@marycrowley.org
mechanisms thereby modulating gene expression. Using a miR30-scaffold, we developed a novel “bifunctional” RNAi strategy, which demonstrated effective silencing of target gene expression by concurrently inducing post-transcriptional RNA-induced silencing complex (RISC) cleavage-dependent mRNA cleavage and RISC cleavage-independent translational repression and p-body sequestration.

We have expanded these observations and have demonstrated significant reduction of EWS/FLI1 gene expression using a novel bi-shRNAi platform and delivery LPX (lipoplex) that resulted in inhibition of Ewing's tumor growth in vitro and safety as well as a survival advantage in vivo.

RESULTS

Target site justification

We identified specific EWS/FLI1 fusion breakpoints and engaged lateral sequence single-step assessment for optimization of the bifunctional shRNA (bi-shRNA) target sequence across the fusion region. The bi-shRNA is specific to EWS/FLI1 type 1 fusion gene. We designed three bi-shRNAs encompassing the fusion mRNA joint region with slightly divergent sequences; plasmids pGBI 140, 141, and 142 (Figure 1b). The expression units for the bi-shRNAs targeted to the type 1 EWS/FLI1 fusion breakpoint was assembled and inserted between the Sal I and Not I sites of mammalian expression vector pUMVC3 from which the shRNA expression is driven by an enhanced pol II CMV promoter (Figure 1a). The final bi-shRNA EWS/FLI1 construct contains two stem-loop structures in a previously described modified miR-30a backbone. One of the stem-loops consists of fully matched passenger and guide strands (RISC cleavage-dependent; the siRNA component), whereas the other stem-loop structure contains four base-pair mismatches between passenger and guide strands (RISC cleavage-independent; the miRNA-like component). The nucleotide mismatches in the latter are at positions 9 to 11 and 17 of the passenger strand, which create a mismatch at the central location and seed region similar to most miRNAs. By placing the mismatches in the passenger strand, the siRNA and miRNA-like guide strands are complementary to the identical mRNA target sequence strand thereby further limiting the potential for off-target side effects. The predicted stem-loop structure of plasmid pGBI 140 is graphically shown on Figure 1c. The targeting sequence was carefully analyzed for potential cross-reactivity to other human miRNAs by BLAST search. The optimum targeting sequence based on our proprietary algorithm with the least off-target side effects, was used to design the expression vector constructs. The Ewing's type 1 construct target sequence and the schematic of the expression plasmid is shown in Figure 1a, b, respectively. The final construct was sequence confirmed in its entirety and then reconfirmed three times as part of GMP DNA and lipoplex manufacturing process.

In vitro activity of bi-shRNA EWS/FLI1 plasmid

Target gene expression knockdown was first tested in vitro. The three constructs of the pbi-shRNA EWS/FLI1 plasmid, vectors pGBI 140, 141 and 142 (spanning the Ewing's type 1 junction region), were tested. SK-N-MC human Ewing's sarcoma cells have the Ewing's type 1 translocation and the type 1 fusion gene expression at the mRNA level was further confirmed using reverse transcription polymerase chain reaction (RT-PCR) (data not shown). The functional outcome of knockdown was demonstrated by selective growth inhibition of the SK-N-MC cells in vitro (Figure 2b). The growth of HEK-293 cells, control cells not containing the EWS/FLI1 fusion, to assess effect on normal, nontranslocated EWS and FLI genes, was not affected even with a 10-fold higher concentration of bi-shRNA EWS/FLI1 DNA exposure. The transfection efficiency for HEK-293 cells and for SK-N-MC cells was monitored by reporter gene and both cell lines were over 80% efficiency. Initial in vitro testing of three bi-shRNA constructs traversing the targeting type 1 fusion region (targeting sequence is shown on Figure 1b) revealed 85–92% knockdown of the fusion gene assayed by FLI1 (Figure 2a) antibody. Although the empty vector (pUMVC3) also affected the expression of fusion protein, the bi-shRNA expressing vector showed the optimal effect. Depending on the gene target and the transfection condition used, we often observe a lower level of target gene expression reduction with the empty vector control possibly due to recovery from the transfection condition. Comparative sequence analysis of the fusion region from EWSR1 and FLI1 demonstrated that the sequence is completely conserved between human, mouse, rat, and pig. Therefore, rodents and pigs are bio-relevant models for efficacy and toxicology analysis of the pbi-shRNA EWS/FLI1 LPX.

In vivo murine efficacy and safety of pbi-shRNA EWS/FLI1 LPX

For in vivo studies, the payload plasmid DNA was complexed with the cationic liposome for systemic delivery. The cationic liposome and DNA complex (lipoplex) have been utilized in numerous in vivo and clinical studies. Lipoplex formulation has been optimized for bi-shRNA EWS/FLI1 vectors. A series of three independent efficacy studies were carried out. The pbi-shRNA EWS/FLI1 LPX demonstrated a reduction in tumor growth and improved survival in a dose-responsive manner in all three independent SK-N-MC Ewing's sarcoma subcutaneous implanted xenograft mouse model studies without adverse or toxic effect. Study mice gained weight throughout the study period; however, no significant differences in body weight were observed between control and treated mice or between low-dose and high-dose cohorts. Survival benefit supported the efficacy of the pbi-shRNA EWS/FLI1 LPX. A statistically significant dose-related tumor growth inhibition was seen in two independent xenograft studies (Studies # e203 and 207, Figure 3a, c). Moreover, a statistically significant dose-related survival advantage was demonstrated in a third xenograft trial (Study # e204, Figure 3b). Notably 100% of high-dose pbi-shRNA EWS/FLI1 LPX-treated xenograft mice were alive at day 28 after dosing initiation compared to less than 20% survival in control mice (study animals were terminated when tumor exceeded the maximum allowed tumor volume). As noted, the tumor response and animal survival benefit was highly significant (P ≤ 0.001) in all studies.

As part of the process of optimization of the manufacture of the pbi-shRNA EWS/FLI1 LPX to improve scale-up opportunity, we reduced product particle size by two- to threefold and minimized variability of size in compliance with FDA recommendations for clinical application. The previous manufacturing technique utilized a thin-film method. The average of 10 independent DNA-Lipoplex batches resulted in a mean particle size
of 426 ± 56 nm with a mean polydispersity index of 0.592 ± 0.115. The optimized manufacturing process utilizes a rapid injection liposome technique. The mean particle size of four independent DNA-Lipoplex was 169 ± 16 nm with a mean polydispersity index of 0.226 ± 0.025. The third xenograft efficacy study (Study # e207) utilized this optimized manufacturing process (Figure 3c). Target gene (measured by FLI-1 antibody) and downstream fusion protein induced gene (CD99) knockdown in vivo was demonstrated by western immunoblot on xenografted tumor tissues after four rounds of treatment with various doses (Study # e208, Figure 4). The fusion gene protein expression knockdown ranged from 64 to 84% (Figure 4, lanes 3–6) with reduction in CD99 protein expression from 21 to 72%. CD99 is a well-known Ewing's induced cell surface protein often used to differentiate Ewing's sarcoma from other sarcomas.50–52 The western assay on in vivo tumor samples was done with small tumor sections sampled from different regions of the whole tumor; although the knockdown percentage varies site to site (a representative results is shown on Figure 4), reduction of target fusion gene expression and induced CD99 expression was consistent. Results shown in Figure 5 display the cytokine response to a single high dose of pbi-shRNA EWS/FLI1 (100 µg IV) in Balb/c mice.

**Cytokine response**

Results are consistent with toxicity response highlighted by transient fever in mini-pigs shown below. Rapid induction of IL6, IL12, and TNF following dosing is observed with return to baseline within 10 hours. Circulating IFNγ was also observed in male mice over the same time course.

**Toxicology dose range study of bi-shRNA EWS/FLI1 LPX in pigs**

A dose range toxicology study was performed in mini-pigs (Charles River Laboratories, Spencerville, OH) to determine the maximum...
dose levels are 0.0846 and 0.2538 mg/kg, respectively. The predicted human equivalents of these
manufacturing process. Two dose levels were tested, 0.128 mg/kg (low) and 0.384 mg/kg (high), equivalent to 25 and 75 µg infusion
per mouse, respectively. The predicted human equivalents of these dose levels are 0.0846 and 0.2538 mg/kg, respectively.

pbi-shRNA EWS/FLI1 LPX-related increases in body temperature were noted 2 to 4 hours following dosing on Days 1 and
5 in both high- and low-dose cohorts. The elevated body temperatures coincided with transient shivering, decreased activity,
and vomiting. An additional dose of Meloxicam (equivalent to acetaminophen use in patients) was administered for temperature
above 104°F (40 °C) within 6 hours after post-dose response. By 24 hours, the body temperatures returned to normal in all pigs.
On Day 5, two high-dose female animals with temperatures above 102°F were administered an additional dose of Meloxicam. None
required Meloxicam intervention after the second treatment.

There were no pbi-shRNA EWS/FLI1 LPX-induced changes in body weight, coagulation parameters, gross pathology, or organ
weights. Transient pbi-shRNA EWS/FLI1 LPX-related decreases up to 80% in the total white blood cell count and neutrophils
were noted in ≥ 0.128 mg/kg-treated animals compared to the controls beginning either 6 or 24 hours post-each dose administration
and continuing through 48 hours. No dose-related adverse effect on renal function was seen based on the serum creatinine and blood
urea nitrogen levels throughout the course of the treatment.

One 0.384 mg/kg male (study animal #7326) displayed decreased activity with tremors, head tilt, and coughing, and was
euthanized on Study Day 21. A thrombus was noted in the right jugular vein at necropsy. This was confirmed microscopically and
attributed to the presence of the venous access port. Microscopic observations of multifocal mild bronchiolalveolar mixed cell
infiltrates and minimal intra-alveolar fibrin suggest a compromise of capillary/alveolar membranes. The justification to sacrifice this
pig was considered related to complications from the vascular access port.

Serological evidence of liver irritation was demonstrated in a subset of the high-dose pigs. Pig #7326, who was terminated early,
had slight rise in bilirubin to 2.85 mg/dl with return to normal on day 3 (0.19 mg/dl); no other significant bilirubin rises were noted
in other pigs. Transient alkaline phosphatase rise was noted in all high-dose pigs and transient increases in GGT levels rarely above
200 U/l was seen in pigs 7326 and 7328. No microscopic liver pathology was observed at final sacrifice (3 days after last dose).
No low-dose pigs showed liver irritation (see Figure 6). The blood alkaline phosphatase level was elevated two to threefold for 2 days
post-treatment after each dosing in the 0.384 mg/kg group. It was only slightly elevated in the 0.128 mg/kg group. Animal #7327 of
the 0.384 mg/kg group had normal alkaline phosphatase level after four doses. Blood AST level transiently elevated eight to ninefold
for #7326 two days after treatment, but was only slightly elevated with subsequent treatment. On the other hand, #7328’s (female,
0.384 mg/kg cohort) had AST elevation amplified as more doses were given. It is not clear why control animal #7319 also had a
significant aspartate aminotransferase (AST) spike on the day 22 post-treatment after each dosing in the 0.384 mg/kg group. It was
only slightly elevated in the 0.128 mg/kg group. Animal #7329 of the 0.384 mg/kg group had normal alkaline phosphatase level after
four doses. Blood AST level transiently elevated eight to ninefold for #7326 two days after treatment, but was only slightly elevated
with subsequent treatment. On the other hand, #7328’s (female, 0.384 mg/kg cohort) had AST elevation amplified as more doses
were given. It is not clear why control animal #7319 also had a significant aspartate aminotransferase (AST) spike on the day 22
dose. #7328 (high dose) had slight increase following the second and third dose. The 0.128 mg/kg cohort had only a slight increase
of blood total bilirubin (TBIL) level on the first day of the first dose, the TBIL level returned to normal with subsequent doses. Blood
GGT level was not elevated for 0.128 mg/kg group, but did
rise three to fivefold in #7326 (high dose) throughout the course of the treatment (Figure 6), it might be worth noting that #7326 already had slightly higher GGT level 6 days prior to treatment. #7328’s GGT elevated following the second dose (which was not typically observed ≥ second dose) and the GGT level was significantly higher throughout. Sporadic low level increases in lactate dehydrogenase (LDH) and creatine kinase (CK) were also noted at 0.128 and 0.384 mg/kg at 6 to 24 hours following dosing. Transient drops in systolic blood pressure to below 90 were considered significant. This was observed in one low-dose pig (#7323) intermittently throughout the course of treatments but not related to time of administration. However, pretreatment transient drops in systolic blood pressure were also observed to a similar degree. This pig also had frequent no readings from the vascular monitoring probe, thereby suggesting sensor probe function variability. The blood pressure readings were not correlated to clinical sequelae. One other pig (#7322, low dose) had a systolic blood pressure of 86 on Day 8 of testing also without other clinical sequelae. These were considered insignificant. No compromise or cardiac work load was observed.

Microscopic findings were observed and included mild to marked thrombosis at the primary administration site (vascular access port) and the presence of numerous granulocytic and mononuclear cells within affected alveoli and bronchioles in the lungs. Thrombosis was evident in variably-sized pulmonary vessels. The pulmonary thrombi were interpreted as a secondary event following embolization from the primary administration site and a possible source for compromise of the capillary wall/alveolar epithelial barrier and local pulmonary circulation. Minimal to moderate interstitial accumulations of mononuclear cells adjacent to airways and vessels were considered secondary to changes occurring within the alveoli. The findings noted in the lung were not considered direct test article effects.

**DISCUSSION**

*In vitro* results confirmed the efficacy of pbi-shRNA EWS/FLI1 LPX with marked knockdown of Ewing’s type 1 fusion protein correlating with tumor growth reduction. Moreover, specificity was observed with no evidence of tumor growth reduction in tumor cells not containing the EWS/FLI1 fusion gene. Humans, rodents, and pigs have identical sequence matching at the exons involved in the translocation of *EWS* and *FLI1* genes, supporting bio-relevance of these animal models for safety studies. Reasonable tolerance was observed in both mice and pigs to pbi-shRNA EWS/FLI1 LPX with acceptable safety at the low dose level of 0.128 mg/
kg (human equivalent of 0.0846 mg/kg). Moreover tumor growth inhibition in multiple Ewing’s type 1 tumor xenograft studies supported efficacy as measured by dose-related tumor response and survival. Demonstration of target gene knockdown in the treated xenografted tumors verified the modality of drug action in correlation with tumor response and survival advantage.

The EWS/FLI1 translocation results in aberrant expression of a novel fusion transcription factor which affects several signal pathways and cellular phenotypes.\(^5^,^6\) We first demonstrated EWSR/FLI1 knockdown in the type 1-specific SK-N-MC cell lines in vitro. SK-N-MC cells are difficult to transfect by standard transfection methods\(^5^,^6\); thus, we used electroporation to effect plasmid delivery in vitro. The electroporation process has limits with respect to cell viability. As demonstrated by western immunoblot analysis, our constructs did efficiently reduce the expression of EWSR/FLI1 fusion protein, but the empty vector control (pUMVC3) also resulted in some reduction of EWSR/FLI1 fusion protein. The housekeeping gene for the load control (Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)) was also lower (when compared with other samples); it appears that there is a generalized reduction in both EWSR/FLI1 and GAPDH proteins. The probing of GAPDH and EWSR/FLI1 was on the same blot and was not related to gel loading. The GAPDH protein expression was not affected in bifunctional shRNA construct transfected cells. Further assessment is underway.

To demonstrate pharmacodynamics, we examined EWSR/FLI1 protein expression in treated tumor compared to untreated tumor or vehicle treated control. As shown on Figure 4, tumors obtained from various dose-treated animals were shown to have significant target protein knockdown. SK-N-MC tumor is a well-vascularized tumor;\(^5^,^6\) thus sections examined by western immunoblot may contain varied numbers of host cells distorting accurate quantification of EWSR/FLI1 protein, which may limit dose-related knockdown efficiency assessment. We also examined CD99 expression, which is highly expressed in Ewing’s sarcoma cells. Although Chromatin Immunoprecipitation (CHIP) analysis in one study suggests EWSR/FLI1 fusion protein binds to the promoter region of CD99, changes in CD99 expression have not been consistent across other studies.\(^6^\) A recent paper suggests the EWS/FLI1 RNAi effect on CD99 expression is effected instead at the post-transcriptional level.\(^6^\) As shown on Figure 4 bottom panel, CD99 protein was substantially reduced. Assessment of dose response was limited but results are consistent with target gene knockdown effect and consequent phenotype control regardless of mechanism. EWSR/FLI1 fusion expression is low, and thus difficult to visualize by immunohistochemistry, which was attempted.

The bi-shRNA platform fulfilled clinical release criteria and demonstrated significant and consistent activity in preclinical and clinical testing in adult and pediatric cancer patients thereby providing further confidence with activity of pbi-shRNA EWS/FLI1 LPX.\(^5^,^6\)

Additional safe preclinical and clinical experience has been described with another bi-shRNA plasmid/LPX delivery vehicle targeting Stathmin 1 (STMN1),\(^5^,^6\) a microtubule modulating protein.\(^6^\) This systemic LPX delivery vehicle which also incorporates 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and cholesterol and is similar in composition to the vehicle used for the bi-shRNA EWS/FLI1 plasmid delivery, demonstrated the predicted stathmin cleavage product via next-generation sequencing as well as by RNA ligase-mediated rapid amplification of cDNA Ends (RLM-RACE) testing of tumor samples from treated patients.\(^5^,^6\)

The delivery vehicle used for bi-shRNAi STMN1 vector delivery as well as other plasmid based products by us\(^5^,^6\) and others\(^5^,^6\) recently has been modified to more explicitly conform to GMP production operation and product release criteria under FDA oversight. This newly modified delivery vehicle was used for the bi-shRNA EWS/FLI1 delivery. The manufactured liposome/DNA Lipoplex (LPX) are uniquely flexible\(^5^,^6\) and effectively penetrate functional and physical barriers including passage against interstitial pressure gradients and into tumors across tight endothelial cell barriers.\(^5^,^6\) The fusogenic nature of LP allows bypassing of endocytosis mediated DNA cell entry, which could otherwise lead to nucleic acid degradation and contribute to toll-like receptor-mediated off-target effects. Early proinflammatory response induced by siRNA with nonviral liposome delivery systems previously showed induced IL-6 levels as high as 500–600 pg/ml 6 hour post-treatment with 50 µg per mouse infusions whereas our data showed our formulation to have a reduced IL-6 induction of 60–170 pg/ml 6 hours post-treatment with double the infusion dose (100 µg) per mouse; the magnitude of cytokine response thus appears significantly lower than observed by others. This may be part of the reason this formulation is better tolerated in mice, even at higher doses, than other reported lipoplex formulations. These other formulations reach MTD between 35 to 50 µg per 20g mouse, a human equivalent dose of 0.118 to 0.169 mg/kg. In our study similar sized mice tolerated
much higher doses. The 0.128 and 0.384 mg/kg dosed mini-pigs reported here received an equivalent of 25 and 75 µg dose per 20g mouse, an human equivalent dose of 0.0846 and 0.2538 mg/kg, respectively.

Most pigs on the treatment arm did experience temperature elevation on the first dosing day. Also, transient elevation of liver function tests was observed in the high-dose cohort but was not significant in the low dose cohort. Findings consistent with central line thrombus dispersion were observed in both control and treated pigs. Although not attributable to pbi-shRNA EWS/FLI1 LPX activity, the embolic pulmonary changes that resulted limited LPX-specific evaluation thus necessitating closer pulmonary monitoring in clinical testing. Notably, the low-dose cohort in this report (human equivalent dose of 0.08 mg/kg/70 kg) is higher than the 0.06 mg/kg dose of lipoplex established as the MTD by Roth et al.49 with IV administration of TUSC2(FUS1)-LPX. Other DNA/liposome therapeutics are associated with a transient flulike syndrome and tachycardia in patients (i.e., SGT-53 (ref. 72)). It is possible that with further dose escalation of the pbi-shRNA EWS/FLI1 LPX platform technology a similar toxicity profile may be observed however, based on the murine and pig experience with pbi-shRNA EWS/FLI1 LPX and human experience with both FURIN and STMN1 bi-shRNA LPX products, there is a high likelihood that effective knockdown of EWS/FLI1 will occur at dose levels below the toxicity limit thereby resulting in an acceptable therapeutic window.

In conclusion, in vivo efficacy with the pbi-shRNA EWS/FLI1 LPX was demonstrated in the Ewing’s Sarcoma xenograft (SK-N-MC) characterized by the type-1 EWS/FLI1 fusion. Tolerance across dose levels was shown to be manageable. These data (in conjunction with previous clinical experience with other bi-shRNA LPX) are the basis for phase 1 testing of pbi-shRNA EWS/FLI1 LPX in poor prognosis patients with advanced Ewing’s sarcoma with the type 1 fusion gene.

MATERIALS AND METHODS

**Cell lines, DNA, liposome, and lipoplex.** SK-N-MC (ATCC HTB-10 Ewing’s sarcoma Type I fusion gene cell line) cells and HEK-293 (embryonic kidney cell line not containing EWS/FLI1 fusion) cells were purchased from ATCC (Manassas, VA). Research-grade plasmid DNA was purchased from Aldevron (Fargo, North Dakota). Waisman Biomanufacturing (Madison, WI) manufactured good manufacturing practice (GMP)-grade bi-shRNA EWS/FLI1 plasmid. GMP-grade liposome and pbi-shRNA EWS/FLI1 LPX was manufactured at Strike Bio (Carrollton, TX). Product release criteria and stability assessments were recently completed (Lot # 031815B-P).

**In vitro growth inhibition.** Cell proliferation assay was conducted by using the CellTiter-Glo Luminescent Cell Viability Assay Reagents by Promega (Madison, WI). Cells were transfected with differing amounts of plasmid DNA via optimized electroporation condition; parallel transfections were performed with reporter expressing plasmids to assess transfection efficiency. Transfected cells were seeded in 96-well opaque-walled culture plates at about 30% confluence. One to two days after transfection, the media were discarded, cells washed once with phosphate-buffered...
**Protein expression by western immunoblot analysis.** Tumor samples were first weighed and homogenized in Celllytic MT Cell Lysis Reagent for mammalian tissues (Sigma, St. Louis, MO) with 1× protease inhibitors (Sigma), 1× phosphatase inhibitors 2 (Sigma) and 1× phosphatase inhibitors 3 (Sigma) at ratio of 10 µl of lysis buffer to 1 mg tumor sample. The homogenates were centrifuged at 14,000 rpm for 10 minutes and the supernatants transferred to a clean tube. The protein concentration was measured using the Bradford method. An appropriated aliquot of tissue lysate from each sample was mixed with 1/3 volume of 4× Laemmli Sample buffer (Bio-Rad, Hercules, CA) with 5% β-mercaptoethanol and heated at 94 °C for 10 minutes. Then, samples were loaded on 4–20% Mini-PROTEAN TGX Precast Gels (Bio-Rad) for electrophoresis. Afterwards, the protein in the gel was transferred to polyvinylidene difluoride membrane using Trans-Blot Turbo Transfer System (Bio-Rad). The membrane was first blocked with 5% non-fat milk in 1× PBS with 0.1% Tween 20 for 1 hour at room temperature, then probed with primary antibody in 5% non-fat milk in 1× PBS with 0.1% Tween 20 overnight at 4 °C. The next day, the membrane was washed three times with 1× PBS with 0.1% Tween 20 and then incubated for 2 hours with horseradish peroxidase-conjugated second goat anti-mouse (sc-2005) or goat anti-rabbit (sc-2004) antibody (Santa Cruz, Dallas, TX). After washing three times with 1× PBS with 0.1% Tween 20, the membrane was incubated with anti-β-actin antibody (C4) from Santa Cruz (1:1000) and then incubated with SuperSignal West Dura Extended Duration Substrate (ThermoFisher Scientific, Waltham, MA) was added to visualize the signal and the signal was captured using the ChemiDoc MP Imaging System (Bio-Rad). To detect EWS/FLI1 fusion protein, 40 μg total protein lysate was loaded to run the gel and anti-FLI1 antibody (AbCam, ab133485) was used. To detect CD99, 10 μg total protein lysate and anti-CD99 antibody (Abcam, ab108297) was used. Anti-β-actin antibody (C4) from Santa Cruz was used for normalization.

---

**Table 1 Mini-pig premedication progression and equivalent patient premedication progression**

| Mini-pig | 24 hours prior | Day 1 | Human | 24 hours prior | Day 1 |
|----------|----------------|------|-------|----------------|------|
|          | Dexamethasone 6 mg IV (0.3 mg/kg) (1 hour prior) | Famotidine 10 mg IV (0.5 mg/kg) (30 minutes prior) | Dexamethasone 6 mg IV (0.3 mg/kg) (30 minutes prior) | 20 mg po qd X5d Aciphex or PPI | 8 mg oral dexamethasone (1 hour prior) |
|          | Dexamethasone 6 mg IV (0.3 mg/kg) (1 hour prior) | Diphenhydramine 12.5 mg IV (0.625 mg/kg) (30 minutes prior) | Meloxicam 4 mg IV (0.2 mg/kg) (30 minutes prior) | 8 mg oral dexamethasone | 8 mg oral dexamethasone (1 hour prior) |
|          | Meloxicam 4 mg IV (0.2 mg/kg) (30 minutes prior) | 25 mg indocin (1 hour prior) | 650 mg acetaminophen (1 hour prior) | | |
**Lipoplex and physical characterization.** The pbi-shRNA EWS/FLI1 LPX final product was manufactured under cGMP conditions (Strike Bio, Carrollton, TX). The manufacturing process follows a modified two-step ethanol injection method. Briefly, appropriate amounts of the lipids (DOTAP + Cholesterol) are weighed out and dissolved in ethanol. The liposomes (LP) are created by rapidly injecting a DOTAP:Cholesterol + Ethanol solution into 5% dextrose (D5W). The ethanol is removed by tangential flow filtration (TFF) with exchanges of D5W to reduce the ethanol concentration to less than 0.5%. The liposomes are then volume adjusted with additional D5W so that the final concentration is 10 mmol/DOTAP and 9 mmol/l Cholesterol. Intermediate quality control is performed to confirm the physical characteristics of the liposomes before moving to the next series of manufacturing steps. The final product is created by rapidly mixing bi-shRNA EWS/FLI1 DNA with the liposomes to generate the pbi-shRNA EWS/FLI1 LPX product, at a concentration of 0.4 mg DNA/ml. The final product is vialized and held in quarantine until completion of all release testing.

Release testing includes LPX physical characterization (OD400, Z-average size, polydispersity index, and zeta potential), DNA identity and integrity analysis (DNA extraction and restriction enzyme digest), and purity assessment (thin layer chromatography, sterility, and endotoxin).

**In vivo efficacy studies.** Three in vivo mouse xenograft studies were designed to evaluate the efficacy of the pbi-shRNA EWS/FLI1 LPX product. All three murine studies were performed by an independent facility, Charles River Laboratories (Morrisville, NC). The first two studies (#e203, e204/e205) utilized our "prior thin film" manufacturing method.\(^1\) The third study (e207/e208) utilized the ethanol injection method described above.

The e203 study. A pilot study, female athymic nude mice were implanted subcutaneously with SK-N-MC xenografts (n = 10 per group) and treatment began when the mean tumor volume was 120–180 mm\(^3\). Mice received a slow IV infusion of test article twice weekly for 4 weeks at a dose of 5 or 25 µg of pbi-shRNA EWS/FLI1 LPX per injection. Body weight and tumor volume were measured twice weekly and individual animals were taken off study when tumor volume reached 2,000 mm\(^3\). Statistical analysis was performed to detect significant differences between treatment groups and the controls.

The e204/e205 study. A follow-up study was performed using four additional doses to assess tumor growth delay (Study e204) and to sample tumor for molecular analysis (Study e205). For Study e204, female athymic nude mice (n = 10 per group) with SK-N-MC xenografts were treated with slow IV infusion twice weekly for 6 weeks. The treatment was started when tumor reached a range of 115–117 mm\(^3\). Four dose levels (25, 18.75, 12.5, and 6.25 µg per infusion) were tested. Study e204 was designed to follow body weight and tumor growth until the maximum allowable tumor volume was reached (similar to study e203 above). Study e205 (two animals per group) was designed to sacrifice all animals after 2 weeks of test article infusions and collect blood and tumor samples for molecular analysis.

The e207/e208 study. A third mouse xenograft study was designed, expanding upon the results of e203/e204/e205 studies. Female athymic nude mice were implanted with SK-N-MC xenografts (n = 10 per group) and treatment began when the tumor size was in the range 100–150 mm\(^3\). The e207/e208 study utilized the improved pbi-shRNA EWS/FLI1 LPX product (rapid injection method: vide infra) allowing for the exploration of higher doses (25µg, 50µg, and 75µg) to test for efficacy and safety. The e207 study followed a twice weekly × 4-week infusion schedule and measured body weight and tumor volume twice weekly until the individual maximum tumor volume was reached. The e208 study was designed to collect blood, kidney, lung, liver, and tumor for molecular analysis, two groups of three animals per group were either not treated or treated for 2 weeks with 75 µg of pbi-shRNA EWS/FLI1 LPX per infusion; animals were sacrificed 1 day after the last infusion.

**Cytokine analysis.** Balb/C mice with average body weight of 20 g received single dose of 100 µg bi-shRNA EWS/FLI1 (Lot # 031815-B-P) via slow tail vein infusion. At designated time points, postinfusion blood was collected via tail vein bleed into K2-EDTA tubes; plasma was prepared and stored at –80 °C before analysis. Cytokines (IFN-γ, TNF-α, IL-12, and IL-6) were assessed using a multiplex protein biomarker detection platform, Luminex MAGPIX system (Life Technologies, Carlsbad, CA). Twenty-five microliters of mouse plasma were first diluted four times in Bioplex Sample Diluent. Fifty microliters of diluted plasma were added to 96-well plate containing beads with covalently coupled capture antibody to cytokines (each bead coupled with one type of capture antibody). At the same time, serial diluted mouse IFN-γ, TNF-α, IL-12, and IL-6 standards were also added to the plate in duplicate. After binding for 30 minutes in a shaker (at 850 rpm) at room temperature, beads were washed with buffer solution three times at room temperature to remove unbound proteins. Then biotinylated detection antibodies were added and incubated for 30 minutes. Unbound detection antibodies were removed by washing with wash solution three times at room temperature. Then SAPE solution was added to each well and signal was read using MAGPIX System. The raw data was further analyzed using Bioplex software and the absolute concentrations of the samples were determined by construction of a standard curve for each analyte.

**ACKNOWLEDGMENTS**

We gratefully acknowledge the generous support of the Alan B. Slifka Foundation, the Carson Sarcoma Foundation, the ChemoWarrior Foundation, Don and Linda Carter, the Helen L. Kay Charitable Trust, The Marilyn Augur Family Foundation, Michele Ashby, the Rutledge Foundation, the Speedyway Children’s Charities, Triumph Over Kid Cancer and the family and friends of Sam Day. The authors would like to acknowledge Michelle Watkins and Brenda Marr for their competent and knowledgeable assistance in the preparation of the manuscript. The following authors are shareholders in Gradalis, Inc. and Strike Bio: D.D.R., C.J., Z.W., J.N., and N.S. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

**REFERENCES**

1. Leavey, PJ and Collier, AB (2008). Ewing sarcoma: prognostic criteria, outcomes and future treatment. *Expert Rev Anticancer Ther* 8: 617–624.

2. Eliaashvili, N, Goodman, M and Marcus, RB Jr (2008). Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. *J Pediatr Hematol Oncol* 30: 425–430.

3. Gambini, G, Cocchi, S, Benini, S, Magagnoli, G, Morandi, L, Kreshak, J et al. (2011). Molecular diagnosis in Ewing family tumors: the Rizzoli experience.-222 consecutive cases in four years. *J Mol Diagn* 15: 313–324.
4. Arvand, A and Denny, CT (2001). Biology of EWS/ETS fusions in Ewing’s family tumors. Oncogene 20: 5747–5754.

5. Timmer, F, Laut-Duc, M, Pantet, A, Delorme, B, Charbond, P and Delattre, O (2007). Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11: 421–429.

6. Riggi, N, Suva, ML, Suva, D, Cironi, L, Provero, P, Terric, S et al. (2008). EWS-FLI1 expression triggered by Ewing’s sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 68: 2176–2185.

7. Meltzer, PS (2007). Is Ewing’s sarcoma a stem cell tumor? Cell Stem Cell 1: 13–15.

8. Kovar, H, Ban, J and Pospisilova, S (2003). Potentials for RNAi in sarcoma research and therapy. Ewing sarcoma as a model. Semin Cancer Biol 13: 275–281.

9. Oikawa, T (2004). ETS transcription factors: possible targets for cancer therapy. Cancer Sci 95: 626–635.

10. Tominsky, JA, Connell, V, Necker, L and Bhat, NK (1997). Inhibition of EWS-FLI1 fusion protein with antisense oligodeoxynucleotides. J Neurosci 31: 9–16.

11. Tanaka, K, Iwakuma, T, Harimaya, K, Sato, H and Iwamoto, Y (1997). EWS-ETSI antisense oligodeoxynucleotide inhibits proliferation of human Ewing’s sarcoma and primitive neuroectodermal tumors cell. J Clin Invest 99: 239–247.

12. Mateo-Lozano, S, Gokhale, PC, Soldatenkov, VA, Dritschilo, A, Tirado, OM and Novikov, S (2006). Combined transcriptional and translational targeting of EWS/FLI1 in Ewing’s sarcoma. Clin Cancer Res 12: 6781–6790.

13. Dohjima, T, Lee, NS, Li, H, Ohno, T and Rossi, JJ (2003). Silencing c-myc in melanoma cells by small interfering RNA expressed from a polarity promoter suppresses the EWS/FLI1 transcript in an Ewing sarcoma cell line. Mol Ther 7: 811–816.

14. Prieur, A, Tirorde, F, Cohen, P and Delattre, O (2004). EWS/FLI1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24: 7272–7281.

15. Nozawa, S, Ohno, T, Ban, Y, Dohjima, T, Wakakura, K, Fan, DG et al. (2005). Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for PDGFR alpha via down-regulation of phospholipase D2 in Ewing sarcoma cells. J Biol Chem 280: 27454–27461.

16. Kinsey, M, Smith, R and Lesnick, SL (2006). RNAi is required for the oncogenic phenotype mediated by EWS/FLI1 in Ewing’s sarcoma. Mol Cell Res 4: 851–859.

17. Herrero-Martin, D, Osuna, D, Ordorique, J, Sevilla, V, Martinis, AS, Mackintosh, C et al. (2009). Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF2 signaling and reduces tumor growth. PLoS One 4: e6079.

18. Hu-Lieskovian, S, Heidel, JD, Bartlett, DW, Davis, ME and Triche, TJ (2005). Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res 65: 8984–8992.

19. Toub, N, Bertrand, JR, Tamaddon, A, Elhames, H, Hillaireau, H, Maksimenko, A et al. (2006). Efficacy of siRNA nanocapsules targeted against the EWS/FLI-1 oncoprotein in Ewing sarcoma. Pharm Res 23: 892–900.

20. Ramon, AL, Bertrand, JR, de Martimprey, H, Bernard, G, Porchez, G, Malvy, C et al. (2013). siRNA associated with immunonanoparticles directed against cdf99 antigen impinges genes expression inhibition in vivo in Ewing’s sarcoma. J Mol Recognit. 65: 36–46.

21. Mautz, C, Tomari, Y, Shin, C, Bartel, DP and Zamore, PD (2005). Passanger-strand interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cell line. Oncogene 24: 607–620.

22. Okazaki, T, Hillmann, A, Hoffmann, C, Rübe, C, Blasius, S, Dunst, J et al. (2011). Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57: 549–553.

23. Ozaki, T, Hillmann, A, Hoffmann, C, Rube, C, Blasius, S, Dunst, J et al. (1996). Significance of surgical margin on the prognosis of patients with Ewing’s sarcoma. A report from the Cooperative Ewing’s Sarcoma Study. Cancer 98: 790–892.

24. Bacci, G, Cicci, P, Ferrari, S, Mercori, M, Brach del Prever, A, Roito, P et al. (1999). Neoadjuvant chemotherapy for Ewing’s sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase. J Clin Oncol 17: 2081–2085.

25. Klinegiebel, T, Perlt, U, Hess, CF, Jurgens, H, Koscielnik, E, Pottter, R et al. (1998). Treatment of children with relapsed soft tissue sarcoma: report of the German CESS 98 trial. J Clin Oncol 16: 2690–2699.

26. Rodriguez-Galindo, C, Billups, CA, Curran, LE, Rao, BN, Pratt, CB, Merchant, TE et al. (2002). Survival after recurrence of Ewing tumors: the St Jude Children’s Research Hospital experience, 1979-1999. Cancer 94: 561–569.

27. Shankar, AG, Ashley, S, Craft, AW and Pinkerton, CR (2003). Outcome after relapse in an unschooled cohort of children and adolescents with Ewing’s sarcoma. Pediatr Blood Cancer 40: 141–147.

28. Barker, LM, Pendegrass, TW, Sanders, JE and Hawkins, DS (2005). Survival after recurrence of Ewing’s sarcoma family of tumors. J Clin Oncol 23: 4354–4362.

29. McTiemer, AM, Cassoni, AM, Driver, D, Michelangeli, MF, Kidby, AM and Whelan, JS (2004). Improving Ewing’s sarcoma. Cancer Gene Ther 11: 861–868.

30. Bacci, G, Ferrari, S, Longhi, A, Donati, D, De Paoli, M, Forin, C et al. (2003). Therapy and survival after recurrence of Ewing’s tumors: the Rizzoli experience in 195 patients treated with adjuvant and nonadjuvant chemotherapy from 1979 to 1997. Ann Oncol 14: 1654–1659.

31. Rasper, M, Jahan, S, Arndt, J, Hauert, J, Marler, S and Dirksen, U (2014). The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer 61: 1382–1386.

32. Navid, F, Billups, C, Liu, T, Krasin, MJ and Rodriguez-Galindo, C (2008). Effect of cranial nerve palsy in patients with Ewing sarcoma family of tumors. Eur J Cancer 44: 983–991.

33. Merchant, TE, Kushner, BH, Sheldon, JM, LaQuaglia, M and Healey, JH (1999). Effect of cranial dose radiation therapy when combined with surgical resection for Ewing sarcoma. Med Pediatr Oncol 33: 65–70.

34. Saylors, RL, 3rd, Stine, KC, Sullivan, J, Kepner, JL, Wall, DA, Bernstein, ML et al. (2001). Pediatric Oncology Group Protocol 0102. Cyclophosphamide plus doxorubicin in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19: 3463–3469.
pbi-shRNA EWS/FLI1 Lipoplex for Ewing’s Sarcoma

65. Jay, CM, Ruoff, C, Kumar, P, Maass, H, Spanhel, B, Miller, M et al. (2013). Assessment of intravenous pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) in yucatan swine. Cancer Gene Ther 20: 683–689.

66. Jay, C, Nemunaitis, G, Nemunaitis, J, Senzer, N, Hinderlich, S, Darvish, D et al. (2008). Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2). Gene Regul Syst Bio 2: 243–252.

67. Wu, J, Liu, S, Yu, J, Zhou, G, Rao, D, Jay, CM et al. (2014). Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform. Cancer Gene Ther 21: 48–53.

68. Liu, SH, Zhou, G, Yu, J. Wu, J, Nemunaitis, J, Senzer, N et al. (2013). Notch1 activation up-regulates pancreatic and duodenal homeobox-1. Genes (Basel) 4: 358–374.

69. Ramesh, R, Saeki, T, Templeton, NS, Ji, L, Stephens, LC, Ito, I et al. (2001). Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 3: 337–350.

70. Judge, AD, Sood, V, Shav, JR, Fang, D, McClinton, K and MacLachlan, I (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457–462.

71. Robbins, M, Judge, A and MacLachlan, I (2009). siRNA and innate immunity. Oligonucleotides 19: 89–102.

72. Senzer, N, Nemunaitis, J, Nemunaitis, D, Bedell, C, Edelman, G, Barve, M et al. (2013). Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther 21: 1096–1103.

73. Nemunaitis, G, Jay, CM, Maples, PB, Gahl, WA, Huizing, M, Yardeni, T et al. (2011). Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex. Hum Gene Ther 22: 1331–1341.

74. Nemunaitis, G, Maples, PB, Jay, C, Gahl, WA, Huizing, M, Poling, J et al. (2010). Hereditary inclusion body myopathy: single patient response to GNE gene lipoplex therapy. J Gene Med 12: 403–412.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/